Genscript Biotech (01548) Slips Over 6% in Morning Trading; JPMorgan Says New U.S. Nucleic Acid Screening Rules Pose a Manageable Issue

Stock News11-11

Genscript Biotech (01548) fell more than 6% in morning trading. As of press time, the stock was down 6.45% at HK$31.64, with turnover of HK$377 million.

On the news front, on November 5, the White House issued a new version of the National Policy for Nucleic Acid Synthesis Screening pursuant to Executive Order 14292. On November 6, the U.S. National Institutes of Health announced that it is fully implementing the policy. On the date of full implementation, the policy will replace the 2024 Nucleic Acid Synthesis Screening Framework as well as other nucleic acid synthesis screening policies that conflict or are inconsistent with it.

JPMorgan stated in a research report that the updated U.S. nucleic acid screening policy represents a manageable issue for Genscript Biotech, rather than a fundamental demand or market access risk. The bank noted that Genscript has promoted responsible gene synthesis practices for many years and self-certified compliance with the U.S. nucleic acid synthesis screening framework in 2024. In addition, revenue from gene synthesis derived from U.S. federally funded projects is expected to be relatively small, so the impact on Genscript's gene synthesis business is expected to be limited.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment